Status:
UNKNOWN
Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Non-small Cell Lung Cancer
Radiation Toxicity
Eligibility:
All Genders
Brief Summary
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curat...
Detailed Description
The investigators propose a longitudinal imaging pilot study composed of 20 Stage I-III NSCLC patients before, and six weeks after standard radiotherapy using a hybrid 3T-PET/MRI system (Biograph mMR,...
Eligibility Criteria
Inclusion
- Age 18 or older
- Ability to provide informed consent
- Histologically confirmed carcinoma of the lung
- Stage I-III NSCLC
- Stage I-II patients to receive 54 Gy in 3 fractions, 55 Gy in 5 fractions, or 60 Gy in 8 fractions (treated every other day)
- Stage III patient to receive concurrent chemoradiation ( 60 Gy in 30 daily fractions)
- No prior RT to the thorax
- ECOG performance status 0-1 within one month of accrual
- Expected lifespan at least 1 year
- Negative pregnancy test within one month of accrual if woman is premenopausal
- Patient presented at multidisciplinary tumor board or quality-assurance rounds
- Satisfactory pulmonary function tests as determined by the treating radiation oncologist (ie. FEV1 \>= 0.8 for Stage III NSCLC and no threshold for Stage I/II).
Exclusion
- Patients receiving Prescription RT dose to anything other than LRCP standards for Stage I-III NSCLC.
- Prior history of atrial fibrillation
- Previous coronary bypass surgery
- Patients with severe reversible airways obstruction
- Patients with acute coronary syndrome (STEMI/non-STEMI and unstable angina)
- AV block without pacemaker
- Patients who are renal insufficient (eGFR \<40)
- Patients with asthma
- Allergy to iodinated contrast for scans (study subject will be eligible for non-contrast scans)
- Use of metformin-containing products less than 24 hours prior to CT contrast administration
- Other contraindications to iodinated contrast media as determined by the research team.
- Allergy to gadolinium for scans using contrast; will be eligible for non-contrast scans.
- Other contraindications to gadolinium contrast media as determined by the research team.
Key Trial Info
Start Date :
January 11 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03416972
Start Date
January 11 2018
End Date
March 1 2020
Last Update
January 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lawson Health Research Institute
London, Ontario, Canada, N6C 2R5